United States securities and exchange commission logo





                          October 5, 2022

       Amir Reichman
       Chief Executive Officer
       BiondVax Pharmaceuticals Ltd.
       Jerusalem BioPark, 2nd Floor
       Hadassah Ein Kerem Campus
       Jerusalem, Israel

                                                        Re: BiondVax
Pharmaceuticals Ltd.
                                                            Registration
Statement on Form F-1
                                                            Filed September 29,
2022
                                                            File No. 333-267648

       Dear Amir Reichman:

              This is to advise you that we have not reviewed and will not
review your registration
       statement.

               Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
       that the company and its management are responsible for the accuracy and
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

                                                        Please contact Benjamin
Richie at 202-551-7857 with any questions.




                          Sincerely,


                          Division of Corporation Finance

                          Office of Life Sciences
       cc:                                              Perry Wildes